On August 23, 2021 Allarity Therapeutics A/S ("Allarity" or the "Company") reported the publication of its Interim Report for the period January – June 2021 (Press release, Allarity Therapeutics, AUG 23, 2021, View Source [SID1234586829]). The report is available as an attached document and on the Company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steve Carchedi, CEO of Allarity Therapeutics, commented on the Company’s accomplishments during the period, stating , "In July, we successfully out-monetized our last remaining secondary pipeline program, irofulven. Shortly after our divestment of Irofulven, we, following positive results of our pre-clinical testing of stenoparib against numerous variants of the original Sars-CoV 2 strain, announced that we are initiating pre-clinical testing of stenoparib for activity against the delta variant (B.1.617.2). Also, in July, we announced that the U.S. Food and Drug Administration had provided a positive administrative acceptance and review notification for our pre-market approval application for our Dovitinib-DRP. Earlier, in June, we announced that our Rights Offering had been oversubscribed, netting approximately U.S. $12 million of crucial working capital. Lastly, in May, we announced that Allarity has entered into an agreement with 3i Fund for a U.S. $20 million investment to support Allarity’s recapitalization and reorganization into a U.S listed company."

Summary of the Interim Report for Q2 2021

Consolidated group revenue amounted to 0 MDKK (0 MDKK).
Consolidated group loss before depreciation amounted to -30.7 MDKK (-5.2 MDKK).
Consolidated group loss before net financials amounted to -89.8 MDKK (-5.5 MDKK).
Consolidated net result amounted to -92.1 MDKK (-3.5 MDKK).
Consolidated earnings per share (EPS) amounted to -0.37 DKK (-0.03 DKK).

2020 numbers in brackets.

Highlights during Q2 2021

April

On April 2, the Company submitted a Pre-Market Approval (PMA) application to the U.S. FDA for the DRP companion diagnostic for dovitinib.
On April 15, the Company published the minutes of the Annual General Meeting 2021.
On April 29, the Company announced that a Dovitinib-DRP e-Poster would be presented at the EACR 2021 Virtual Congress to be held from 9-12 June 2021.

May

On May 19, the Company announced that it would conduct a Rights Issue of new shares, and it had published a prospectus regarding the Rights Issue.
On May 21, the Company announced that it had secured an investment from 3i Fund for recapitalization, transition to listing on U.S. Nasdaq, and advancing the Company’s pipeline of priority oncology therapeutics.
On May 28, the Company published the Interim Report for the period January – March 2021

June

On June 9, the Company published an E-Poster detailing the molecular pathways covered by the Dovitinib-DRP companion diagnostic
On June 10, the Company announced that the rights issue had been oversubscribed
On June 14, it was announced that Allarity Therapeutics and Oncoheroes Biosciences had to partnered on pediatric cancer development of dovitinib and stenoparib
On June 24, the last day of trading with Allarity Therapeutics A/S BTU was announced

Highlights after the period

July

On July 5, the Company received an acceptance and review notification from U.S. FDA for Pre-Market Approval application for Dovitinib-DRP
On July 26, it was announced that the Company and Lantern Pharma entered into an agreement for Future Clinical Development of Irofulven
August

On August 5, the Company announced that its oral PARP inhibitor, stenoparib, had demonstrated pre-clinical antiviral activity against new variants of Coronavirus
On August 16, a notice to convene an Extraordinary General Meeting on August 31, 2021, was announced